Navigation Links
Brain Tumor Drug May Help Spur Cancer's Return
Date:3/5/2009

But insights into how that happens may lead to ways around it, researchers say,,,,

THURSDAY, March 5 (HealthDay News) -- Temozolomide, a standard treatment for brain cancer, may boost the aggressiveness of surviving cancer cells, making tumor recurrence more likely, a new study suggests.

The research team, from Memorial Sloan-Kettering Cancer Center in New York City, have identified cells in brain tumors called gliomas that have stem cell-like qualities and are able to survive chemotherapy with the help of a particular protein. These surviving cells become drug-resistant, and may be the reason treatment for brain cancer is usually unsuccessful.

"Stem-like cells are found in brain tumors, and the mutations that occur in high-grade tumors promote the stem cell character of tumor cells," explained lead researcher Dr. Eric Holland, director of Sloan-Kettering's Brain Tumor Center. "Furthermore, the standard therapy for brain tumors -- although beneficial against many of the tumor cells -- actually promotes stem cell character in the cells that survive."

The report is published in the March 6 issue of Cell Stem Cell.

According to the American Cancer Society, nearly 22,000 Americans were diagnosed with a malignant tumor of the brain or spinal cord in 2008, and more than 13,000 died from these cancers. Brain tumors also gained prominence this past year after Sen. Ted Kennedy (D-Mass.) was diagnosed with a particularly aggressive type of cancer known as a malignant glioma.

For the new study, Holland's team looked at the role of the protein ABCG2, which is associated with resistance to drugs in brain cancer cells. This protein transports drugs across the cell's membrane, which would otherwise shield the tumor cell from chemotherapy drugs, Holland explained.

The researchers isolated cells from mice and human cancer brain tumors called glioblastomas. Some of these cells appeared to have the ability to renew themselves and resist chemotherapy, the team found, and ABCG2 appears to be a marker for these resistant cells.

Holland's group also identified how the protein helps tumor cells expel chemotherapy drugs.

"Current treatment for gliomas works for a while and then usually fails," Holland said. "These findings might be partly the reason for that. There is more than one cell type in these tumors, and they respond differently to the therapy we treat people with."

For example, the chemotherapy drug temozolomide -- which is the standard treatment for gliomas -- actually increased the number of drug-resistant cells. Because temozolomide doesn't target ABCG2, it may render surviving cells more resistant to treatments that do target the ABCG2 protein, Holland theorized.

"Life is complicated; brain tumors are complicated, too," he said.

Dr. Ronald Benveniste is an assistant professor of neurosurgery at the University of Miami School of Medicine. He believes the study has a real upside because it points to new, longer-lasting brain cancer treatments.

"Clinically, what we see with patients with glioblastoma is that after surgery, radiation and chemotherapy with temozolomide, they live longer and a subset of them will actually live a year, two years or even longer. And then pretty much 100 percent of the patients relapse and no one knows why," Benveniste said.

This study identifies the mechanism by which this happens, he said. "When you treat mice with temozolomide they develop recurrent diseases even quicker, so temozolomide make the cells that survive act in a more aggressive manner," Benveniste said.

"In the future, relapse after treatment with temozolomide could be prevented by inhibiting these pathways," he speculated. "This could open doors to treatment. This is exciting stuff."

More information

For more information on brain tumors, visit the U.S. National Library of Medicine .



SOURCES: Eric Holland, M.D., Ph.D., director, Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York City; Ronald Benveniste, M.D., assistant professor, neurosurgery, University of Miami School of Medicine; March 6, 2009, Cell Stem Cell


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Brain tumor treatment may increase number of cancer stem-like cells
2. European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
3. Now Hear This: Brain Fitness Exercises Improve Listening
4. Nearly 1.4 Million Sustain Traumatic Brain Injuries Each Year
5. National Council on Disability Says More Needs to be Done for Service Members and Veterans With Post Traumatic Stress Disorder and Traumatic Brain Injury
6. Brain Adapts to Age-Related Eye Disease
7. UCI scientists to study brain region linked to autism, schizophrenia
8. Schizophrenia linked to signaling problems in new brain study
9. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
10. Sex is in the brain, says new research from Stanford
11. Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Brain Tumor Drug May Help Spur Cancer's Return
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology: